Your browser doesn't support javascript.
loading
Prediction and characterization of diffuse large B-cell lymphoma cell-of-origin subtypes using targeted sequencing.
Trabucco, Sally E; Sokol, Ethan S; Maund, Sophia L; Moore, Jay A; Frampton, Garrett M; Albacker, Lee A; Oestergaard, Mikkel Z; Venstrom, Jeffrey; Sehn, Laurie H; Bolen, Christopher R.
Afiliação
  • Trabucco SE; Foundation Medicine, Inc., Cambridge MA 02141, USA.
  • Sokol ES; Foundation Medicine, Inc., Cambridge MA 02141, USA.
  • Maund SL; Genentech, Inc., South San Francisco, CA 94080, USA.
  • Moore JA; Foundation Medicine, Inc., Cambridge MA 02141, USA.
  • Frampton GM; Foundation Medicine, Inc., Cambridge MA 02141, USA.
  • Albacker LA; Foundation Medicine, Inc., Cambridge MA 02141, USA.
  • Oestergaard MZ; F. Hoffmann-La Roche Ltd., Basel, 4070, Switzerland.
  • Venstrom J; Foundation Medicine, Inc., Cambridge MA 02141, USA.
  • Sehn LH; BC Cancer Centre for Lymphoid Cancer & University of British Columbia, Vancouver, BC, V5Z 1L3, Canada.
  • Bolen CR; Genentech, Inc., South San Francisco, CA 94080, USA.
Future Oncol ; 17(31): 4171-4183, 2021 Nov.
Article em En | MEDLINE | ID: mdl-34313135
ABSTRACT
The aim of the present study was to determine cell of origin (COO) from a platform using a DNA-based method, COO DNA classifier (COODC). A targeted exome-sequencing platform that applies the mutational profile of a sample was used to classify COO subtype. Two major mutational signatures associated with COO were identified Catalogue of Somatic Mutations in Cancer (COSMIC) signature 23 enriched in activated B cell (ABC) and COSMIC signature 3, which suggested increased frequency in germinal center B cell (GCB). Differential mutation signatures linked oncogenesis to mutational processes during B-cell activation, confirming the putative origin of GCB and ABC subtypes. Integrating COO with comprehensive genomic profiling enabled identification of features associated with COO and demonstrated the feasibility of determining COO without RNA.
Lay abstract To determine subtypes of diffuse large B-cell lymphoma (DLBCL), a cancer with poor survival, we aimed to identify DLBCL subtypes using DNA mutation-based tools. A targeted gene-sequencing platform, which measures the number and types of DNA mutations in a sample, was used to categorize DLBCL subtypes. Two major patterns of mutations associated with subtypes were identified Catalogue of Somatic Mutations in Cancer (COSMIC) signature 23 and COSMIC signature 3. Differences in how the subtypes developed suggest a link between tumor developments and B cells being activated normally, confirming where the DLBCL subtypes came from. Combining this information with comprehensive genomic profiling, which determines all of the genes that a person has, allowed identification of features that are associated with DLBCL subtypes and showed that a DLBCL subtype can be determined without using RNA.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B / Sequenciamento de Nucleotídeos em Larga Escala Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B / Sequenciamento de Nucleotídeos em Larga Escala Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article